Navigation

Appraisals in development

This table lists NICE technology appraisals. The list can be sorted by title (alphabetically), wave number, anticipated publication date and process. You can also click the appraisal title for full details, or click a column heading to sort the list by that column.

Appraisals in development

Results 61-80 of 152

Title Anticipated publication date Referral date Process
Juvenile idiopathic arthritis - adalimumab [ID385] TBC Jun 2008 STA
Kidney disease (autosomnal dominant polycystic) - tolvaptan [ID652] TBC Oct 2013 STA
Kidney transplantation (rejection) - belatacept [ID87] TBC Jul 2009 STA
Kidney transplantation (rejection) - everolimus [ID117] TBC Jul 2009
Knee cartilage defects - autologous chondrocyte implantation [ID686] Jul 2015 Oct 2013 MTA
Leukaemia (acute lymphoblastic) - dasatinib [ID386] TBC Jun 2008 STA
Leukaemia (chronic lymphocytic) - obinutuzumab (with chlorambucil, 1st line) [ID650] Feb 2015 Dec 2013 STA
Leukaemia (chronic lymphocytic, previously untreated) - ofatumumab [ID642] Apr 2015 Oct 2013 STA
Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79] May 2011 Mar 2009 STA
Lung cancer (non small cell, EGFR mutation positive) - afatinib [ID556] Apr 2014 STA
Lung cancer (non small cell, non squamous) - pemetrexed (maintenance following pemetrexed & cisplatin) [ID489] Apr 2014 Feb 2012 STA
Lung cancer (non-small cell) - afatinib [ID357] TBC Jul 2010 STA
Lung cancer (non-small cell) - erlotinib & gefitinib (post chemotherapy) (rev TA162, TA175) [ID620] Jun 2014 MTA
Lung cancer (non-small cell) - nintedanib [ID438] Apr 2015 Dec 2013 STA
Lung cancer (non-small-cell) - cetuximab [ID9] TBC Dec 2007 STA
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] TBC Nov 2008 STA
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] TBC Nov 2008 STA
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46] TBC Nov 2008 STA
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407] TBC Nov 2010 STA
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609] TBC May 2012 STA

This page was last updated: 17 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.